BioNTech SE - ADR

NASDAQ:BNTX   3:59:56 PM EDT
130.22
+2.57 (+2.01%)
Products, Regulatory

BioNTech says Pfizer-BioNTech Omicron Ba.4/Ba.5 Covid-19 Bivalent Vaccine Available To Ship Immediately

Published: 08/31/2022 14:23 GMT
BioNTech SE - ADR (BNTX) - Pfizer and Biontech Granted FDA Emergency Use Authorization of Omicron Ba.
4/ba.
5-adapted Bivalent Covid-19 Vaccine Booster for Ages 12 Years and Older.
Biontech Se - Application for an Omicron-adapted Bivalent Vaccine for Children 5 Through 11 Years of Age is Planned for Submission to FDA in Early October.
Biontech Se - Pfizer-biontech Omicron Ba.
4/ba.
5 Covid-19 Bivalent Vaccine Available to Ship Immediately.
Biontech Se - Companies Are Working With FDA to Prepare an Application for an Omicron-adapted Bivalent Vaccine in Children 6 Months Through 4 Years of Age.
Biontech Se - Original Pfizer-biontech Covid-19 Vaccine Will Remain Available As a Booster Dose for Children 5 Through 11 Years of Age.
Biontech Se - Will File a New Supplemental Biologics License Application (sbla) for the Omicron-ba.
4/ba.
5 Bivalent Booster Vaccine.
Biontech Se - Will Supply the Original and Bivalent Vaccines Under Their Existing Supply Agreement With the U.S. Government.